Clinical Research and the Advantages of Operating Clinical Trials in Large Countries

Clinical research is the key towards discovery ofclinical experts, set up an Expert Committee and
most current diagnostic strategies and to developformulated their GCP guideline for generation of
current drugs for treatment of illnesses.clinical data on drugs. An endorsement of the
Good Clinical Practice (GCP) is an ethical and scientificadoption of this GCP guideline for streamlining the
high quality standard for developing, performing andclinical studies in India was made by the Drug
recording trials that involve the involvement ofTechnical Advisory Board, the highest technical body
individual clients. Complying with this standard ofunder D&C.
compliance offers peace of mind to the public thatInvestigation associations, investigators, institutional
their legal rights, safety and well-being of trial patientsethics committees and regulators will find that this
are safe, and steady with the principles encompassedconfidence within their guideline will be profoundly
from the Declaration of Helsinki and guarantees thatbeneficial to in offering desired direction. Organizations
clinical trial information is credible.who may want to locate their clinical programme
It is commonly regarded that numerous nationswithin their country will also find the guideline
including those in Europe, United States and Indiabeneficial.
offers distinctive opportunities for executing clinicalUnless there is a comprehensive training program to
trials in view of their large patient pool, well-trainedsupport these recommendations and polices then
and avid investigators and premiere medicalpeople involved throughout performing the studies will
organizations readily available within these nations.only be paying lip service to the standards. This is
Additionally, India also has sizeable low per patient trialone fact that does not change no matter who
cost, when compared with developed countries.produces legislation or regulations to follow
To develop country specific recommendations withinthroughout clinical studies, and this should not
India, it was believed however that there was aneglected, For example, who takes ultimate
need to make certain uniform high quality of clinicalresponsibility for the training prerequisites within an
research throughout the country and to generateindustry that could be considered to be
data for registration for new drugs before use inself-regulatory, and one of the issues surrounding this
their Indian population. The Central Drugs Standardis that there needs to be more regulation for the gcp
Control Organisation (CDSCO) in consultation withcourses training programs.